A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Conditions
- Locally Advanced Solid TumorsMetastatic Solid Tumors
- Interventions
- Registration Number
- NCT03093116
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Brief Summary
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction.
Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
- Detailed Description
In Phase 2, study subjects will be enrolled into 6 distinct expansion (EXP) cohorts:
* EXP-1: ROS1 TKI-naïve ROS1+ NSCLC. Up to one prior line of chemotherapy OR immunotherapy is allowed
* EXP-2: 1 Prior ROS1 TKI AND 1 Platinum-based Chemotherapy ROS1+ NSCLC. Disease progression, or intolerant to one prior line of a ROS1 TKI. Must have received one prior line of platinum based chemotherapy OR one prior line of platinum based chemotherapy in combination with immunotherapy before or after a ROS1 TKI
* EXP-3: 2 Prior ROS1 TKIs AND NO Chemotherapy ROS1+ NSCLC. Disease progression, or intolerant to 2 prior lines of a ROS1 TKI treatment. No prior lines of chemotherapy or immunotherapy are allowed.
* EXP-4: 1 Prior ROS1 TKI and NO Chemotherapy or Immunotherapy. Disease progression or intolerant to one prior line of a ROS1 TKI. No prior lines of chemotherapy or immunotherapy are allowed.
* EXP-5: TRK TKI-naïve NTRK+ solid tumors. Any number of prior lines of chemo or immunotherapy is allowed.
* EXP-6: TRK TKI-pretreated NTRK+ solid tumors. Disease progression, or intolerant to 1 or 2 prior TRK TKIs. Any number of prior lines of chemo- or immunotherapy are allowed.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 500
- Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) (Stage IV, American Joint Committee on Cancer v.7) that harbors an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement by protocol specified tests.
- ECOG PS 0-1.
- Age ≥18 (or age ≥ 20 of age as required by local regulation).
- Capability to swallow capsules intact (without chewing, crushing, or opening).
- At least 1 measurable target lesion according to RECIST version 1.1. CNS-only measurable disease as defined by RECIST version 1.1 is allowed.
- Prior cytotoxic chemotherapy is allowed.
- Prior immunotherapy is allowed.
- Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1.
- Patients with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria.
- Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine clearance Within normal limits or > 40 mL/min; Total serum bilirubin < 1.5 × ULN; Liver transaminases (ASTs/ALTs) < 2.5 × ULN; < 5 × ULN if liver metastases are present Alkaline phosphatase (ALP); < 2.5 × ULN; < 5 × ULN if liver and/or bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation
- Life expectancy ≥ 3 months.
PHASE 2 Key Inclusion Criteria
-
Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) that harbors a ROS1, or NTRK1-3 gene fusion.
-
Subject must have a documented ROS1 or NTRK1-3 gene fusion determined by tissue-based local testing using either:
-
a next-generation sequencing (NGS) or quantitative polymerase chain reaction (qPCR) test will be accepted to determine molecular eligibility.
• Adequate tumor tissue needs to be sent to the Sponsor designated central diagnostic laboratory for retrospective confirmation by a central diagnostic laboratory test selected by the Sponsor.
OR
-
a fluorescence in situ hybridization (FISH) test AND prospective confirmation of fusion status by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment will be accepted to determine molecular eligibility.
- Adequate tumor tissue must be sent to the Sponsor designated central diagnostic laboratory for prospective confirmation by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment.
-
-
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
-
Age ≥12 (or age ≥ 20 as required by local regulation).
-
Willing and able to provide written institutional review board (IRB)/institutional ethics committee-approved Informed Consent or an Assent signed by a parent or legal guardian for subjects age 12 to 17.
-
At least 1 measurable target lesion according to RECIST (v1.1) prospectively confirmed by Blinded Independent Central Radiology Review (BICR), selected by Sponsor, PRIOR to enrollment. Subjects with CNS-only measurable disease ≥10 mm as defined by RECIST (v1.1) are eligible.
-
Subjects with advanced solid tumors harboring ROS1, NTRK1, NTRK2, or NTRK3 rearrangement will be assigned into 6 distinct expansion (EXP) cohorts provided all inclusion and exclusion criteria are met.
i. EXP-1: ROS1 TKI-naïve ROS1+ NSCLC ii. EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC iii. EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO) iv. EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO) v. EXP-5: TRK TKI-naïve NTRK+ solid tumors vi. EXP-6: TRK TKI-pretreated NTRK+ solid tumors
-
Subjects with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria.
-
Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine clearance > 40 mL/min; Total serum bilirubin < 1.5 × ULN; Liver transaminases (ASTs/ALTs) < 2.5 × ULN; < 5 × ULN if liver metastases are present Alkaline phosphatase (ALP); < 2.5 × ULN; < 5 × ULN if liver and/or bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation
-
Life expectancy ≥ 3 months.
Key Exclusion Criteria PHASE 1 and PHASE 2
-
Concurrent participation in another therapeutic clinical trial.
-
Symptomatic brain metastases or leptomeningeal involvement.
-
History of previous cancer, except for squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected, requiring therapy within the previous 2 years.
-
Major surgery within 4 weeks of start of repotrectinib treatment. Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. Palliative radiation (≤10 fractions) must have been completed at least 48 hours prior to study entry
-
Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment): myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association Classification Class ≥ II), cerebrovascular accident or transient ischemic attack, symptomatic bradycardia, requirement for anti-arrhythmic medication. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2
-
Any of the following cardiac criteria:
Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTcF) > 470 msec obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval > 250 msec) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval.
-
Known active infections (bacterial, fungal, viral including HIV positivity).
-
Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption.
-
Peripheral neuropathy of CTCAE ≥grade 2.
-
History of extensive, disseminated, bilateral, or presence of CTCAE grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis. Subjects with history of prior radiation pneumonitis are not excluded.
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Repotrectinib (TPX-0005) Oral repotrectinib (TPX-0005) Phase 1 Oral repotrectinib (TPX-0005): Phase 1a dose escalation, Phase 1b food-effect sub-study, and Phase 1c dose escalation with food, and Midazolam drug-drug interaction sub-study. Phase 2 Oral repotrectinib (TPX-0005): 6 distinct expansion cohorts * EXP-1: ROS1 TKI-naïve ROS1+ NSCLC * EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC * EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO) * EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO) * EXP-5: TRK TKI-naïve NTRK+ solid tumors * EXP-6: TRK TKI-pretreated NTRK+ solid tumors
- Primary Outcome Measures
Name Time Method Overall Response Rate (ORR) Phase 2 Two to three years after first dose of repotrectinib dose To determine the confirmed ORR of repotrectinib (TPX-0005) as assessed by Blinded Independent Central Review (Phase 2)
Dose limiting toxicities (DLTs) (Phase 1) Within 28 days of the first repotrectinib dose Define the dose limiting toxicities (DLTs) (Phase 1)
Recommended Phase 2 Dose (RP2D) (Phase 1) Within 28 days of the last patient dosed in escalation To determine the RP2D (Phase 1)
- Secondary Outcome Measures
Name Time Method Area under the plasma concentration time curve (AUC) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1) Up to 72 hours post dose To determine the area under the plasma concentration time curve (AUC) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1)
Area under the plasma concentration time curve (AUC) of midazolam(TPX-0005) (Phase 1) Up to 24 hours post dose To determine the area under the plasma concentration time curve (AUC) of midazolam(TPX-0005) (Phase 1)
Plasma concentration of repotrectinib following administration at RP2D (Phase 2) Pre dose and 4 hours post dose To evaluate the plasma concentration of repotrectinib following administration at RP2D (Phase 2)
Preliminary objective response rate (ORR) (Phase 1) Approximately three years To determine the preliminary objective response rate (ORR) by Blinded Independent Central Review (BICR) (Phase 1)
Progression free survival (PFS) (Phase 2) Approximately three years To determine the PFS (Phase 2)
Overall survival (OS) (Phase 2) Approximately three years To determine the OS (Phase 2)
Area under the plasma concentration time curve (AUC) of repotrectinib (TPX-0005) (Phase 1) Up to 72 hours post dose To determine the area under the plasma concentration time curve (AUC) of repotrectinib
Maximum plasma concentration (CMAX) of midazolam(TPX-0005) (Phase 1) Up to 24 hours post dose To determine the maximum plasma concentration (CMAX) of midazolam(TPX-0005) (Phase 1)
Maximum plasma concentration (CMAX) of repotrectinib (TPX-0005) (Phase 1) Up to 72 hours post dose To determine the maximum plasma concentration (CMAX) of repotrectinib (TPX-0005)
Duration of response (DOR) (Phase 2) Approximately three years To determine the DOR of repotrectinib (TPX-0005) (Phase 2)
Maximum plasma concentration (CMAX) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1) Up to 72 hours post dose To determine the maximum plasma concentration (CMAX) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1)
Intracranial objective response rate (Phase 2) Approximately three years To determine the intracranial objective response rate (Phase 2)
Clinical benefit rate (CBR) (Phase 2) Approximately three years To determine the CBR of repotrectinib (TPX-0005) (Phase 2)
Trial Locations
- Locations (160)
Local Institution - 6504
🇨🇳Shatin, Hong Kong, China
City Of Hope
🇺🇸Duarte, California, United States
Local Institution - 2120
🇺🇸Glendale, California, United States
Local Institution - 2136
🇺🇸La Jolla, California, United States
UC San Diego Health
🇺🇸La Jolla, California, United States
Pacific Shores Medical Group
🇺🇸Long Beach, California, United States
UC Irvine Medical Center
🇺🇸Orange, California, United States
University of California Irvine Medical Center
🇺🇸Orange, California, United States
St Joseph Heritage Healthcare
🇺🇸Santa Rosa, California, United States
Local Institution - 1003
🇺🇸Aurora, Colorado, United States
University Of Colorado Denver
🇺🇸Aurora, Colorado, United States
Georgetown University Medical Center - Lombardi Comprehensive Cancer Center
🇺🇸Washington, District of Columbia, United States
Local Institution - 2110
🇺🇸Washington, District of Columbia, United States
Memorial Healthcare System
🇺🇸Hollywood, Florida, United States
Local Institution - 2113
🇺🇸Tampa, Florida, United States
University Cancer and Blood Center
🇺🇸Athens, Georgia, United States
Local Institution - 2134
🇺🇸Columbus, Georgia, United States
University of Chicago
🇺🇸Chicago, Illinois, United States
Local Institution - 2142
🇺🇸Peoria, Illinois, United States
Local Institution - 2116
🇺🇸New Orleans, Louisiana, United States
University of Maryland Medical Center
🇺🇸Baltimore, Maryland, United States
Massachusetts General Hospital,
🇺🇸Boston, Massachusetts, United States
Local Institution - 1004
🇺🇸Boston, Massachusetts, United States
Dana Farber Cancer Institute.
🇺🇸Boston, Massachusetts, United States
Local Institution - 2105
🇺🇸Ann Arbor, Michigan, United States
Local Institution - 2111
🇺🇸Detroit, Michigan, United States
Henry Ford Transplant Institute
🇺🇸Detroit, Michigan, United States
Local Institution - 2132
🇺🇸Saint Paul, Minnesota, United States
Local Institution - 2147
🇺🇸Bolivar, Missouri, United States
Washington University Infusion Center Pharmacy
🇺🇸Saint Louis, Missouri, United States
Local Institution - 2122
🇺🇸New Brunswick, New Jersey, United States
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
🇺🇸New York, New York, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
Local Institution - 2144
🇺🇸Goldsboro, North Carolina, United States
Local Institution - 2112
🇺🇸Canton, Ohio, United States
Trihealth Cancer Institute
🇺🇸Cincinnati, Ohio, United States
Local Institution - 2109
🇺🇸Cleveland, Ohio, United States
The Ohio State University Wexner Medical Center
🇺🇸Columbus, Ohio, United States
Local Institution - 2119
🇺🇸Toledo, Ohio, United States
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
Baptist Memorial Hospital Baptist Cancer Center
🇺🇸Memphis, Tennessee, United States
UT Southwestern Medical Center
🇺🇸Dallas, Texas, United States
Local Institution - 2127
🇺🇸Houston, Texas, United States
MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Local Institution - 2146
🇺🇸Kingwood, Texas, United States
Virginia Cancer Specialists, PC
🇺🇸Fairfax, Virginia, United States
University of Washington-Seattle Cancer Care Alliance
🇺🇸Seattle, Washington, United States
Local Institution - 2141
🇺🇸Tacoma, Washington, United States
ThedaCare
🇺🇸Appleton, Wisconsin, United States
Chris O'Brien LifeHouse
🇦🇺Camperdown, New South Wales, Australia
Flinders Medical Centre
🇦🇺Adelaide, South Australia, Australia
Peter MacCallum Cancer Centre
🇦🇺Melbourne, Victoria, Australia
Peter MacCallum Cancer Centre - East Melbourne
🇦🇺East Melbourne, Australia
Uza (University Hospital Antwerp)
🇧🇪Antwerp, Belgium
UZ Leuven PHARMACY CLINICAL TRIALS
🇧🇪Leuven, Belgium
Cross Cancer Institute.
🇨🇦Edmonton, Alberta, Canada
Local Institution - 2205
🇨🇦Vancouver, British Columbia, Canada
Local Institution - 6503
🇨🇦Toronto, Ontario, Canada
Princess Margaret Cancer Centre
🇨🇦Toronto, Ontario, Canada
William Osler Health System
🇨🇦Ontario, Canada
The Ottawa Hospital
🇨🇦Ottawa, Canada
Local Institution - 6702
🇨🇳Beijing, Beijing, China
Beijing Cancer hospital
🇨🇳Beijing, Beijing, China
Daping Hospital, the Third Affiliated Hospital of Third Military Medical University /Cancer Center
🇨🇳Daping, Chongqing, China
Local Institution - 6719
🇨🇳Fuzhou, Fujian, China
The First Affiliated hospital of Xiamen University-oncology
🇨🇳Xiamen, Fujian, China
Guangdong Provincial People'S Hospital
🇨🇳Guangzhou, Guangdong, China
Local Institution - 6733
🇨🇳Guangzhou, Guangdong, China
Local Institution - 6505
🇨🇳Shenzhen, Guangdong, China
The Affiliated Tumor Hospital of Harbin Medical University
🇨🇳Harbin, Heilongjiang, China
Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology/Cancer Center Department
🇨🇳Wuhan, Hubei, China
Local Institution - 6705
🇨🇳Changsha, Hunan, China
Hunan Cancer Hospital-thoracic oncology II
🇨🇳Changsha, Hunan, China
Local Institution - 6748
🇨🇳Nanjing, Jiangsu, China
XuZhou Central Hospital/Oncology Department
🇨🇳Xuzhou City, Jiangsu, China
Jilin Cancer Hospital/Medical Oncology Department
🇨🇳Changchun, Jilin, China
The first hospital of Jilin university-Oncology Department
🇨🇳Changchun, Jilin, China
Liaoning Cancer Hospital
🇨🇳Shenyang, Liaoning, China
Tangdu Hospital
🇨🇳Xi'an, Shan3xi, China
Shanxi Bethune Hospital
🇨🇳Taiyuan, Shanxi, China
Sichuan Cancer Hospital/Medical Oncology Department
🇨🇳Chengdu City, Sichuan, China
The First Hospital Affiliated To AMU - Southwest Hospital
🇨🇳Chongqing, Sichuan, China
Local Institution - 6725
🇨🇳Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital-Oncology
🇨🇳Hangzhou, Zhejiang, China
The Third Xiangya Hospital of Central South University/Department of Respiratory and Critical Care Medicine
🇨🇳Changsha, China
West China Hospital Sichuan University/Lung cancer center
🇨🇳Chengdu, China
The First Affiliated Hospital - Zhejiang University School of Medicine
🇨🇳Hangzhou, China
Anhui Provincial Hospital
🇨🇳Hefei, China
Shanghai Chest Hospital
🇨🇳Shanghai, China
Weifang People's Hospital/Medical Oncology Department
🇨🇳Weifang City, China
Henan Cancer Hospital/The 1st pneumology department
🇨🇳Zhengzhou, China
Local Institution - 4901
🇩🇰Copenhagen, Denmark
Hopital De La Timone
🇫🇷Marseille, Bouches-du-Rhône, France
Local Institution - 4207
🇫🇷Brest, France
Centre Georges-Francois Leclerc
🇫🇷Dijon Cedex, France
Centre Hospitalier Universitarie Grenoble Alpes (Chuga)
🇫🇷Grenoble Cedex 9, France
Centre Antoine-Lacassagne
🇫🇷Nice, France
Chu Poitiers
🇫🇷Poitiers, France
Local Institution - 4203
🇫🇷St Mande, France
Institute Gustave Roussy
🇫🇷Villejuif, France
Local Institution - 4704
🇩🇪Berlin, Germany
University Clinic Carl Gustav Carus
🇩🇪Dresden, Germany
University Hospital Heidelberg
🇩🇪Heidelberg, Germany
Centrum für Integrierte Onkologie - Universitaetsklinikum Koeln
🇩🇪Koln, Germany
Local Institution - 6502
🇭🇰Hong Kong, Hong Kong
Local Institution - 6501
🇭🇰Hong Kong, Hong Kong
Semmelweis Egyetem
🇭🇺Budapest, Hungary
Országos Korányi TBC és Pulmonológiai Intézet
🇭🇺Budapest, Hungary
Fondazione IRCCS Istituto Nazionale dei Tumori
🇮🇹Milano, MI, Italy
Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico
🇮🇹Milano, Italy
Local Institution - 4307
🇮🇹Palermo, Italy
Centro di Riferimento Oncologico
🇮🇹Pordenone, Italy
Local Institution - 4304
🇮🇹Ravenna, Italy
Arcispedale Santa Maria Nuova
🇮🇹Reggio Emilia, Italy
IRCCS Istituto Regina Elena Oncologia Medica 2
🇮🇹Roma, Italy
Azienda Ospedaliera Santa Maria Terni
🇮🇹Terni, Italy
Ehime University Hospital
🇯🇵Toon, Ehime, Japan
Hokkaido University Hospital
🇯🇵Sapporo-shi, Hokkaido, Japan
Kanagawa cancer center
🇯🇵Yokohama, Kanagawa, Japan
Osaka City General Hospital
🇯🇵Osaka-shi, Osaka, Japan
National Cancer Center Hospital.
🇯🇵Chuo-ku, Tokyo, Japan
Tottori University Hospital
🇯🇵Yonago, Tottori, Japan
National Cancer Center Hospital East
🇯🇵Kashiwa, Japan
Nagoya University Hospital
🇯🇵Nagoya-shi, Japan
Osaka International Cancer institute
🇯🇵Osaka, Japan
Samsung Medical Center
🇰🇷Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
Chonnam National University Hwasun Hospital
🇰🇷Hwasun-eup, Hwasun-gun, Jeonnam, Korea, Republic of
Yonsei University Health System
🇰🇷Seoul, Seodaemun-gu, Korea, Republic of
Local Institution - 3002
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
Chungbuk National University Hospital
🇰🇷Cheongju-si, Korea, Republic of
Local Institution - 3001
🇰🇷Seoul, Korea, Republic of
Yonsei University Health System, Severance Hospital
🇰🇷Seoul, Korea, Republic of
Local Institution - 6307
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Seoul Saint Mary's Hospital
🇰🇷Seoul, Korea, Republic of
The Netherlands Cancer Institute
🇳🇱Amsterdam, Netherlands
Universitair Medisch Centrum Groningen
🇳🇱Groningen, Netherlands
Ośrodek Badań Klinicznych Wczesnych Faz, Uniwersyteckie Centrum Kliniczne
🇵🇱Gdańsk, Poland
Local Institution - 4604
🇵🇱Lublin, Poland
Local Institution - 4605
🇵🇱Poznań, Poland
Local Institution - 4603
🇵🇱Szczecin, Poland
Klinika Nowotworow Pluca i Klatki Piersiowej
🇵🇱Warszawa, Poland
National University Hospital
🇸🇬Singapore, Singapore
National Cancer Center Singapore
🇸🇬Singapore, Singapore
Hospital Universitario Dexeus - Grupo Quironsalud
🇪🇸Barcelona, Spain
Hospital Unversitario Val D'Hebrón
🇪🇸Barcelona, Spain
Fundacion Md Anderson
🇪🇸Madrid, Spain
START Madrid-FJD
🇪🇸Madrid, Spain
Hospital Universitario 12 De Octubre
🇪🇸Madrid, Spain
Hospital Universitario HM Sanchinarro CIOCC
🇪🇸Madrid, Spain
Clinica Universidad de Navarra
🇪🇸Pamplona, Spain
Instituto Valenciano de Oncología (IVO) - Unidad de Investigación Clínica FINCIVO
🇪🇸Valencia, Spain
Local Institution - 6201
🇨🇳Taiepi, Taiwan
Local Institution - 6203
🇨🇳Tainan, Taiwan
Local Institution - 6202
🇨🇳Taipei, Taiwan
The Royal Marsden NHS Foundation Trust
🇬🇧Sutton, United Kingdom
Local Institution - 4402
🇬🇧London, United Kingdom
Sarah Cannon Research Institute Central Office
🇬🇧London, United Kingdom
The Christie NHS Foundation Trust
🇬🇧Manchester, United Kingdom